{"DataElement":{"publicId":"3131881","version":"1","preferredName":"Metastatic Breast Carcinoma Estrogen Receptor Detection Method Text","preferredDefinition":"The free-text field to capture the method of measurement used to detect the status of the estrogen receptor in a metastatic breast cancer sample. e.g., dextran coated charcoal.","longName":"3131879v1.0:2018274v1.0","context":"NCIP","contextVersion":"1","DataElementConcept":{"publicId":"3131879","version":"1","preferredName":"Metastatic Breast Carcinoma Estrogen Receptor Detection Method","preferredDefinition":"A term referring to the clinical or pathologic observation of a tumor extension from its original site of growth to another anatomic site._A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit.  Breast carcinoma may affect both females and males.  It is the most common malignant tumor and the leading cause of carcinoma death in women.  Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation.  The widespread use of mammography has contributed in the detection of very early cancerous lesions (less than 2mm in diameter).  The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular).  Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route.  The most common site of lymph node involvment is the axilla.  Breast carcinomas infrequently occur in males (particularly elderly individuals and patients with Klinefelter's syndrome).  The therapy of breat carcinoma includes surgery, radiation therapy, hormonal therapy and chemotherapy, depending on the type and extend of the disease. --2002_information related to the method of determining or identifying the estrogen receptor, cytoplasmic proteins that bind estrogens and migrate to the nucleus where they regulate DNA transcription, status.","longName":"3131866v1.0:2542380v1.0","context":"NCIP","contextVersion":"1","ObjectClass":{"publicId":"3131866","version":"1","preferredName":"Metastatic Breast Carcinoma ER","preferredDefinition":"(MET-uh-STAT-ik) Having to do with metastasis, which is the spread of cancer from one part of the body to another.:A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit.  Breast carcinoma may affect both females and males.  It is the most common malignant tumor and the leading cause of carcinoma death in women.  Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation.  The widespread use of mammography has contributed in the detection of very early cancerous lesions (less than 2mm in diameter).  The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular).  Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route.  The most common site of lymph node involvment is the axilla.  Breast carcinomas infrequently occur in males (particularly elderly individuals and patients with Klinefelter's syndrome).  The therapy of breat carcinoma includes surgery, radiation therapy, hormonal therapy and chemotherapy, depending on the type and extend of the disease. --2002:Widely expressed human Estrogen Receptors (NR3 Family) are ligand-activated nuclear hormone receptor transcription factors composed of an N-terminal transcription activation/modulation domain, a DNA-binding domain, and a C-terminal steroid-binding domain. Binding to DNA as a homo- or heterodimer, ESR interacts with NCOA3, NCOA5, and NCOA6 coactivators. Hormone-ESR complexes appear to recognize discrete upstream target ERE DNA sequences to regulate gene expression, cell proliferation, and differentiation. DNA-binding is lost in the absence of ligand. (NCI)","longName":"C14174:C4872:C17069","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Metastatic","conceptCode":"C14174","definition":"A term referring to the clinical or pathologic observation of a tumor extension from its original site of growth to another anatomic site.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Breast Carcinoma","conceptCode":"C4872","definition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Estrogen Receptor Family","conceptCode":"C17069","definition":"Widely expressed human Estrogen Receptors (NR3 Family) are cytoplasmic hormone-activated receptors that act as nuclear transcription factors composed of an N-terminal transcription activation/modulation domain, a DNA-binding domain, and a C-terminal steroid-binding domain. Binding to DNA as a homo- or heterodimer, ESR interacts with NCOA3, NCOA5, and NCOA6 coactivators. Hormone-ESR complexes appear to recognize discrete upstream target ERE DNA sequences to regulate gene expression, cell proliferation, and differentiation. DNA-binding is lost in the absence of ligand. (NCI)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9333B6-1428-4680-E040-BB89AD433D39","latestVersionIndicator":"Yes","beginDate":"2010-08-24","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-24","modifiedBy":"ONEDATA","dateModified":"2010-08-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2542380","version":"1","preferredName":"Detection Technique","preferredDefinition":"No value exists.:A practiced and regimented skill or series of actions.","longName":"C16210:C16847","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Detection","conceptCode":"C16210","definition":"The act of perceiving, discerning, discovering, or identifying.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Technique","conceptCode":"C16847","definition":"A practiced and regimented skill or series of actions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2251187B-F081-07DF-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-11-15","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-11-15","modifiedBy":"ONEDATA","dateModified":"2006-11-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008549","version":"1","preferredName":"Involvement and Extent of Disease","preferredDefinition":"indication of the presence and extent of disease.","longName":"INV_AND_EXT_OF_DZ","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22AA815-A017-5261-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9333B6-1519-4680-E040-BB89AD433D39","latestVersionIndicator":"Yes","beginDate":"2010-08-24","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-24","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2018274","version":"1","preferredName":"Diagnosis Text","preferredDefinition":"the free text field to specify the diagnosis.","longName":"DX_TXT","context":"CTEP","contextVersion":"2.31","type":"Non-enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2184342","version":"1","preferredName":"Text","preferredDefinition":"Text; the words of something written.","longName":"Text","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Text","conceptCode":"C25704","definition":"The words of something written.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DB6C8AC6-2103-3E75-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-05-27","endDate":null,"createdBy":"SBREXT","dateCreated":"2004-05-27","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2055B67-4F83-69AE-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"CAMPBELB","dateModified":"2004-11-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2756809","version":"1","longName":"TCGA (The Cancer Genome Atlas)","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6044923","version":"1","longName":"Active CDEs as of March 2017","context":"NCIP"}]},{"publicId":"3787498","version":"1","longName":"TCGA 2.6 by Disease","context":"NCIP","ClassificationSchemeItems":[{"publicId":"3787500","version":"1","longName":"BRCA","context":"NCIP"}]}],"AlternateNames":[{"name":"metastatic_breast_carcinoma_estrogen_receptor_detection_method_text","type":"TCGA_XML_Name","context":"NCIP"}],"ReferenceDocuments":[{"name":"Define method of calculation","type":"Preferred Question Text","description":"Define method of calculation for ER Positivity (Metastatic)","url":null,"context":"NCIP"}],"origin":"TCGA:The Cancer Genome Atlas","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9333B6-152A-4680-E040-BB89AD433D39","latestVersionIndicator":"Yes","beginDate":"2010-08-24","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-24","modifiedBy":"TSESU","dateModified":"2018-07-12","changeDescription":"Curated for The Cancer Genome Atlas (TCGA) per request of T. Lichtenberg 8/2010","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}